DUBLIN - It's not over until it's over. Celgene Corp.'s fabled business development engine is still cranking out deals, even though its acquisition by Bristol-Myers Squibb Co. now looks likely to close this year, following this week's $13.4 billion divestment of Otezla (apremilast) to Amgen Inc. Read More
HONG KONG – At the recent Beyond Paradigm Summit 2019 in Kuala Lumpur, a Malaysian company unveiled the country's first humanoid robot. ADAM, an acronym for Advanced Development Autonomous Machine, is built for natural speech and the detection of emotions. While still early in its development, ADAM represents a leap that Malaysia, and perhaps Southeast Asia, is making in the realm of artificial intelligence (AI). Read More
PERTH, Australia – There is pervasive use of artificial intelligence and machine learning (AI/ML) across the health care industry in Australia, and excitement is building on the opportunities it offers to technologies and ultimately to patients, Ausbiotech CEO Lorraine Chiroiu told BioWorld. Read More
From the research point of view, making induced pluripotent stem cells (iPSCs) is perhaps not exactly easy, but routine rather than a heroic effort. Read More
Newark, Calif.-based Protagonist Therapeutics Inc.'s third-quarter earnings call included an update on hepcidin mimetic PTG-300 in beta-thalassemia, but other prospects in the pipeline are starting to excite investors as well. Read More
Genisphere LLC, of Hatfield, Pa., and University Hospitals Cleveland Medical Center will study and develop strategies to treat pancreatic cancer. Projects include delivering a variety of therapeutic cargos, including small molecules and siRNA, formulated with pancreatic tumor-targeting molecules. Read More
Confirming reports that it's in talks to settle more than 2,000 lawsuits related to its marketing of opioid products for what could be billions of dollars, Purdue Pharma LP told BioWorld that "a constructive global resolution is the best path forward, and the company is actively working with the state attorneys general and other plaintiffs to achieve this outcome." Read More
Emerald Health Therapeutics Inc., of Vancouver, British Columbia, said it entered into a binding term sheet with a single Canadian institutional accredited investor for the purchase of 2,500 secured convertible debenture units at $10,000 each for gross proceeds of $25 million. The company intends to use the net proceeds to repay an outstanding loan to Emerald Health Sciences Inc. and the remainder for working capital. Read More
Torque Therapeutics Inc., of Cambridge, Mass., appointed Sok Cheng Soh chief financial officer and Ana Radeljevic vice president, head of business operations. Read More
The Asia Pacific region (APAC) is vast and awash with varied economies, languages, governments and ambitions. That's the backdrop for its dramatic underperformance compared to the West's pharmaceutical innovations. Yet plenty of opportunities exist, along with a healthy dose of uncertainty, according to the first Pharmaceutical Innovation in the APAC region report, published by Clarivate Analytics plc. Read More
